Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Immune Response Against Viral Pathogens01:29

Immune Response Against Viral Pathogens

The immune system's response to viral infections is a complex and coordinated process involving natural killer (NK) cells, T cell-mediated responses, and antibody-mediated responses.
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Relationship Between Radiocapitate Distance as a Structural Parameter and Clinical Outcomes After Volar Locking Plate Fixation of Distal Radius Fractures.

Journal of hand surgery global online·2026
Same author

[Bacterial Meningitis].

Brain and nerve = Shinkei kenkyu no shinpo·2026
Same author

[Anti-leucine-rich glioma-inactivated 1 antibody-positive encephalitis with a poor response to corticosteroids 2 months after onset of impaired memory: a case report].

Rinsho shinkeigaku = Clinical neurology·2026
Same author

Concomitant infectious foci in community-acquired bacterial meningitis: the clinical impact of concomitant spondylitis and endocarditis.

BMC infectious diseases·2025
Same author

Novel in-frame duplication variant of <i>SOD1</i> in a Japanese family with familial amyotrophic lateral sclerosis.

Amyotrophic lateral sclerosis & frontotemporal degeneration·2025
Same author

Traumatic Ulnar Dislocation of the Thumb Carpometacarpal Joint: A Case Report.

Hand (New York, N.Y.)·2025

Related Experiment Video

Updated: May 16, 2026

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4
09:29

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4

Published on: August 21, 2017

Interferon-β1b increases Th2 response in neuromyelitis optica.

Hideto Nakajima1, Takafumi Hosokawa, Yoshimitu Doi

  • 1Division of Neurology, Department of Internal Medicine I, Osaka Medical College, Takatsuki, Osaka 569-8686, Japan. in1045@poh.osaka-med.ac.jp.

International Journal of Molecular Sciences
|December 4, 2012
PubMed
Summary

Interferon beta-1b (IFN-β1b) effectively treats multiple sclerosis (MS) by reducing relapses. However, it may worsen neuromyelitis optica (NMO) by increasing Th2 immune responses, indicating different therapeutic mechanisms.

More Related Videos

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

Related Experiment Videos

Last Updated: May 16, 2026

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4
09:29

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4

Published on: August 21, 2017

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

Area of Science:

  • Neuroimmunology
  • Immunotherapy
  • T-cell responses

Background:

  • Interferon beta-1b (IFN-β1b) is effective for multiple sclerosis (MS) but not neuromyelitis optica (NMO).
  • Differential immune responses to IFN-β may explain varying treatment efficacy in MS and NMO.
  • Investigating chemokine receptor expression on T-cells can elucidate treatment response differences.

Purpose of the Study:

  • To longitudinally assess chemokine receptor expression (CCR5, CXCR3, CCR4) on T-cells in NMO and MS patients undergoing IFN-β1b therapy.
  • To correlate changes in T-cell chemokine receptor expression with clinical outcomes (relapse rates).
  • To understand the immunological basis for differential responses to IFN-β1b in NMO versus MS.

Main Methods:

  • Longitudinal analysis of blood samples from NMO and MS patients over 12 months of IFN-β1b treatment.
  • Flow cytometry to quantify CCR5, CXCR3, and CCR4 expression on CD4+ and CD8+ T-cells.
  • Comparison of chemokine receptor expression and annualized relapse rates before and after treatment.

Main Results:

  • IFN-β1b decreased relapse rates in MS but not in NMO patients.
  • No significant baseline differences in chemokine receptor expression between NMO and MS groups.
  • IFN-β1b treatment reduced Th1-associated cells (CD4+CCR5+, CD4+CXCR3+) in both NMO and MS.
  • IFN-β1b treatment decreased Th2-associated cells (CD4+CCR4+) in MS but significantly increased them in NMO.

Conclusions:

  • IFN-β1b therapy induces a Th2-predominant immune response in NMO patients.
  • This IFN-β1b-induced Th2 up-modulation in NMO may underlie the lack of therapeutic benefit and potential worsening.
  • Th2 pathway involvement is implicated in the pathogenesis of NMO, differentiating it from MS immunopathology.